key: cord-0768194-td3ui4iu authors: Vizuete, Adriana Fernanda K.; Gonçalves, Carlos-Alberto title: Can dexamethasone prevent the seizures induced by SARS-CoV-2 infection? date: 2020-10-27 journal: Mult Scler Relat Disord DOI: 10.1016/j.msard.2020.102606 sha: 01a70ca5e93437ba5b325594cc854468c00f8ce4 doc_id: 768194 cord_uid: td3ui4iu nan recent study reported that dexamethasone was able to reduce the mortality in COVID-19 patients. Considering that dexamethasone abrogated neuroinflammation and improved astrocyte function in a refractory animal model of epilepsy and reduced seizures in refractory patients, it may be speculated that this steroid, in addition to reducing mortality, could prevent and/or mitigate convulsive and other neurological manifestations in COVID-19 patients. A recent article published by Nikbakht et al. in this journal discussed potential mechanisms of seizure and epilepsy in COVID-19 patients [1] . In fact, COVID-19 affects many systems other than the respiratory system, including the cardiovascular, renal and nervous systems. Neurological manifestations are varied, ranging from a headache and anosmia to convulsion and stroke [2] [3] [4] . These manifestations can be provoked either by a direct viral invasion, since neurons and astrocytes have membrane proteases such as ACE-2 and TMPRSS2 that anchor the entry of Sars-CoV-2, as well as by an inflammatory disorder caused by the cytokine storm described in the disease, as pointed out by Nikbakht et al [1] . These data reinforce the idea that an active neuroinflammatory process may be at the basis of epileptic diseases, particularly those resistant to antiepileptic drugs. The cytokine storm has been associated with severe and lethal cases of COVID-19 [5] , where IL-6 could mediate an exacerbated acute phase response by liver, that in turn could explain, in part, the incidence of atypical coagulopathy in these cases [6] . Based on such evidence, the use of immunomodulators has been proposed to control the severity of the disease [7] . A recent trial suggested that dexamethasone reduces mortality in these patients [8] . Interestingly, in a refractory model of epilepsy, dexamethasone was able to abrogate neuroinflammatory signs and improve astrocyte function [9] ; in fact, this anti-inflammatory steroid has been proposed as an adjuvant therapy in cases of refractory epilepsy [10] . Therefore, we speculate that dexamethasone, beyond reducing mortality, could be useful for preventing or mitigating convulsive manifestations in COVID-19 patients. Current investigations of the use of dexamethasone in COVID-19 patients will clarify this question and may be able to evaluate the outcome of other neurological manifestations during and post-COVID-19. How does the COVID-19 cause seizure and epilepsy in patients ? The potential mechanisms Nervous system involvement after infection with COVID-19 and other coronaviruses Ait Benali S. Neuroinvasion, neurotropic, and neuroinflammatory events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients Neurological Manifestations of COVID-19: A systematic review and current update The cytokine storm and COVID-19 Serum amyloid A protein has been undervalued as a biomarker of COVID-19 COVID-19: Review on latest available drugs and therapies against SARS-CoV-2 Coagulation and inflammation cross-talking Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report Effects of dexamethasone on the Lipilocarpine model of epilepsy: Protection against hippocampal inflammation and astrogliosis Dexamethasone as Abortive Treatment for Refractory Seizures or Status Epilepticus in the Inpatient Setting The authors gratefully acknowledge to public funding agencies in Brazil:National Council for Scientific and Technological Development (CNPq) and Coordination for the Improvement of Higher Education Personnel (CAPES) The authors declare no conflicts of interest.